Results 311 to 320 of about 602,416 (352)

Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease. [PDF]

Oncologist
Zhang S, Zhou J, Zhao X, Gan H, Peng W, Li W, Sun M, Hu J, Yan W.   +8 more
europepmc   +1 more source

Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation. [PDF]

CPT Pharmacometrics Syst Pharmacol
Zunino C, Wang S, Zhang Y, Urdy S, de Witte WEA, Declèves X, Puszkiel A, Djebli N.   +7 more
europepmc   +1 more source

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC. [PDF]

Front Oncol
Ramlau R, Kowalski DM, Szczęsna A, Szczylik C, Ou Y, Köbel M, Siegers GM, Gaspar KJ, Lee B, Roszkowski-Sliz K.   +9 more
europepmc   +1 more source

Efficacy and safety of antibody-drug conjugates in the treatment of non-small cell lung cancer: a systematic review and meta-analysis of prospective clinical trials

Xiaoni Jin, Weixing Zhao, Bo Li, Yujia Gu, Zirui Li, Wanjing Guo, Xinxin Lü, Jun Jiang   +7 more
openalex   +1 more source

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. [PDF]

Cell Rep Med
High PC, Liang Z, Guernsey-Biddle C, Subramanian S, Shyu YM, Aldana AM, Toh Y, Carmon KS.   +7 more
europepmc   +1 more source

An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia. [PDF]

Blood Neoplasia
Gordon PM, Williams RL, Ostergaard J, Lee KC, Bui HN, Muretta JM, Wilson BS, Beder T, Baldus CD, Lambert L, Deonovic BE, Singleton T, Tasian SK, Winter SS.   +13 more
europepmc   +1 more source

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy. [PDF]

World J Urol
Kessler C, von Brandenstein M, Klümper N, Krausewitz P, Storz E, Rieger C, Sperber L, Paffenholz P, Tolkach Y, Wirtz R, Eckstein M, Heidenreich A, Weiten R.   +12 more
europepmc   +1 more source

Supplementary Figure S2 from Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models

Sonia Jain, Jessica I. Griffith, Kendra A. Porath, Sneha Rathi, Jiayan Le, Tugce I. Pasa, Paul A. Decker, Shiv K. Gupta, Zeng Hu, Brett L. Carlson, Katrina K. Bakken, Danielle M. Burgenske, Thomas M. Feldsien, Didier R. Lefebvre, Rachael A. Vaubel, Jeanette E. Eckel‐Passow, Edward B. Reilly, William F. Elmquist, Jann N. Sarkaria   +18 more
openalex   +1 more source

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Signal Transduction and Targeted Therapy, 2022
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to ...
Sifei Han, Chen Shi, Yu Zhang
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.

Journal of Clinical Oncology, 2023
1022 Background: Optimizing sequential use of Antibody Drug Conjugates (ADCs) is an area of unmet need and of rising clinical importance. With the recent approvals of sacituzumab govitecan (SG) for HR+/HER2- and triple negative metastatic breast cancer ...
R. Abelman, Laura M. Spring, G. Fell, P.K. Ryan, N. Vidula, A. Medford, J. Shin, E. Abraham, Seth A. Wander, S. Isakoff, B. Moy, L. Ellisen, A. Bardia   +12 more
semanticscholar   +1 more source